The results of these studies may also lead to innovative clinical trials, such as treating older patients with anemia of inflammation with anti-inflammatory agents or hepcidin antagonists such as agents that inhibit hepcidin production (e.g., anti-interleukin 6 receptor antibodies), hepcidin-neutralizing antibodies, targets against hepcidin binding site of ferroportin, or agents that inhibit ferroportin internalization [81]. This evidence concerns the gene SLC40A1 and anemia (phenotype).